APA (7th ed.) Citation

Algorta, J., Diaz, M., de Benito, R., Lefebvre, M., Sicard, E., Furtado, M., . . . Ronchi, C. (2017). Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg). The European journal of contraception & reproductive health care, 22(6), 429-438. https://doi.org/10.1080/13625187.2017.1413179

Chicago Style (17th ed.) Citation

Algorta, Jaime, Maria Diaz, Raquel de Benito, Marc Lefebvre, Eric Sicard, Milton Furtado, Pedro Antonio Regidor, and Celestino Ronchi. "Pharmacokinetic Bioequivalence, Safety and Acceptability of Ornibel®, a New Polymer Composition Contraceptive Vaginal Ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) Compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)." The European Journal of Contraception & Reproductive Health Care 22, no. 6 (2017): 429-438. https://doi.org/10.1080/13625187.2017.1413179.

MLA (9th ed.) Citation

Algorta, Jaime, et al. "Pharmacokinetic Bioequivalence, Safety and Acceptability of Ornibel®, a New Polymer Composition Contraceptive Vaginal Ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) Compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)." The European Journal of Contraception & Reproductive Health Care, vol. 22, no. 6, 2017, pp. 429-438, https://doi.org/10.1080/13625187.2017.1413179.